The effects of lilalucopeptide combined with alendronate on bone mineral density and serum BGP, s-ctx and BAP levels in patients with type 2 diabetes mellitus and osteoporosis.

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2018
This article has no abstract
Epistemonikos ID: cb5646fcb86cb296926c0b362299174524357e25
First added on: Apr 07, 2025